PositoAI/ US/ Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc.

NasdaqGS: IAM · Healthcare

Positivity Index

#6,430 / 6,775

Global

#3,689 / 3,999

United States

Positivity Score

-19,308

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Iambic Therapeutics, Inc. — Overview & Financial Snapshot

Iambic Therapeutics, Inc. (NasdaqGS: IAM) is a Healthcare company, ranked #6,430 of 6,775 companies globally and #3,689 of 3,999 in United States on PositoAI, with a Positivity Score of -19,308. Its market capitalisation is ₹6,406.66 Cr ($675.94M), P/E ratio is -5.3 and P/B ratio is -1.45. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #7 Impact BioMedical Inc. 26,324 #13 Onconetix, Inc. 25,899 #16 Revelation Biosciences, Inc. 25,763 #17 BioStem Technologies, Inc. 25,743

— Nothing to show —

OpenAI is reading recent news...

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

P/B Ratio -1.45

P/E Ratio -5.3

D/E Ratio 0.03

ROE —

Owes vs Owns ? —Not available

Dividend Yield 0.00%

Trailing EPS ₹-254.96$-2.69

Forward EPS —

Beta —

Market Cap ₹6,406.66 Cr$675.94M

What these numbers mean →

What does Iambic Therapeutics, Inc. do?

What is Iambic Therapeutics, Inc.'s P/E and P/B ratio?

Iambic Therapeutics, Inc. has a P/E ratio of -5.3 and a P/B ratio of -1.45.

What is Iambic Therapeutics, Inc.'s debt-to-equity ratio?

Iambic Therapeutics, Inc. has a debt-to-equity ratio of 0.03.

What is Iambic Therapeutics, Inc.'s Positivity rank?

Iambic Therapeutics, Inc. is ranked #6,430 of 6,775 companies globally and #3,689 of 3,999 in United States on PositoAI, with a Positivity Score of -19,308.

Does Iambic Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Iambic Therapeutics, Inc..

Where can I read the latest news about Iambic Therapeutics, Inc.?

Recent headlines about Iambic Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Iambic Therapeutics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Iambic Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.